title: Altretamine (hexamethylmelamine) in the treatment of platinum-resistant ovarian cancer: a phase II study.
abstract: OBJECTIVE
  To evaluate the activity of oral Altretamine in women with epithelial ovarian carcinoma who responded (PR or CR) to first line chemotherapy but relapsed within 6 months. The protocol was later amended to include patients with relapse within 12 months.
  
  
  METHODS
  A multicentric phase II trial. The patients had to have measurable disease. No more than one prior chemotherapy regiment was allowed. The patients were treated with 260 mg/m(2)/day of Altretamine in four divided doses for 2 weeks, repeated every 4 weeks. The response was evaluated after every two courses.
  
  
  RESULTS
  Thirty-one eligible patients were treated with a median of 3 courses of Altretamine (range 1-12). Hematological toxicity was minimal. Gastrointestinal toxicity was common. Response evaluation was possible for 26 patients. Three patients (9.7% intent-to-treat) achieved a partial response. Eight patients had stable disease, and 15 patients had progressive disease after two treatment courses. The median time to progression was 10 weeks (range, 5-51 weeks). Medial survival was 34 weeks (range, 7-112+).
  
  
  CONCLUSIONS
  Altretamine should not be chosen as standard treatment in patients with platinum-resistant recurrent ovarian cancer. However, Altretamine represents a useful alternative in patients who prefer oral treatment or when socioeconomic considerations are an important issue.
authors.affiliation: Department of Oncology, Herning Hospital, Herning, Denmark. hecnk@ringamt.dk
authors.forename: Nina
authors.initials: N
authors.lastname: Keldsen
authors.forename: Hanne
authors.initials: H
authors.lastname: Havsteen
authors.forename: Ignace
authors.initials: I
authors.lastname: Vergote
authors.forename: Kamma
authors.initials: K
authors.lastname: Bertelsen
authors.forename: Anders
authors.initials: A
authors.lastname: Jakobsen
mesh_terms: D000284:Administration, Oral; D000368:Aged; D006585:Altretamine / Q000009:adverse effects / Q000627:therapeutic use*; D018906:Antineoplastic Agents, Alkylating / Q000009:adverse effects / Q000627:therapeutic use*; D019008:Drug Resistance, Neoplasm; D005260:Female; D006801:Humans; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D010051:Ovarian Neoplasms / Q000188:drug therapy*
chemical_list: D018906:Antineoplastic Agents, Alkylating; D009944:Organoplatinum Compounds; D006585:Altretamine